Celyad Oncology (Celyad Oncology) 3-Year EBITDA Growth Rate : 6.40% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology 3-Year EBITDA Growth Rate?

Celyad Oncology's EBITDA per Share for the three months ended in Jun. 2023 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 6.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 20.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Celyad Oncology was 39.80% per year. The lowest was -31.90% per year. And the median was 3.60% per year.

Competitive Comparison of Celyad Oncology's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Celyad Oncology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's 3-Year EBITDA Growth Rate falls into.

Celyad Oncology 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Celyad Oncology (OTCPK:CYADY) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Celyad Oncology 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (Celyad Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.